A mouse model of melanoma driven by oncogenic KRAS.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20516123.
- Also identified by DOI 10.1158/0008-5472.CAN-09-4254 and PMC identifier 2896549.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The small G-protein NRAS is mutated in 22% of human melanomas, whereas the related proteins KRAS and HRAS are mutated in only 2% and 1% of melanomas, respectively. We have developed a mouse model of melanoma in which Cre recombinase/LoxP technology is used to drive inducible expression of (G12V)KRAS in the melanocytic lineage. The mice develop skin hyperpigmentation, nevi, and tumors that bear many of the cardinal histopathology features and molecular characteristics of human melanoma. These tumors invade and destroy the underlying muscles and cells derived from them can grow as subcutaneous tumors and colonize the lungs of nude mice. These data establish that oncogenic KRAS can be a founder event in melanomagenesis.
Medical subject headings
- Cell Transformation, Neoplastic
- Melanoma, Experimental
- Proto-Oncogene Proteins p21(ras)
- Skin Neoplasms